Intraocular injection of KH902 alleviates retinal hypoxia in a mouse model of oxygen-induced retinopathy
2021
Inhibition of vascular endothelial growth factor (VEGF) has been widely
applied in antineovascularization therapies. As a novel anti-VEGF agent,
KH902 (conbercept) is designed to restrain pathological angiogenesis.
However, the effects of KH902 on retinal hypoxia have not been well studied.
In a mouse model of oxygen-induced retinopathy (OIR), we assessed retinal
hypoxia at postnatal days 14 (P14) and P17, as well as retinal
neovascularization (RNV) at P17. In addition, we evaluated the protein level
of VEGF and galectin-1 (Gal-1). Changes of the neuroretinal structure were
also examined. Our results indicated that KH902 could remit retinal hypoxia
in OIR at P14 and P17, which was an exciting novel finding for KH902
function. Additionally, we confirmed that KH902 markedly reduces RNV. Our
results indicated that administration of KH902 downregulated VEGF
expression, as well as Gal-1. Damage of neuroretinal structure after KH902
injection was not observed, which was also an encouraging result. Our study
suggests that KH902 plays a role in alleviating retinal hypoxia and that it
could be used for the treatment of other neovascular ocular diseases.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI